We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Bristol Myers Squibb (BMY - Free Report) is expected to reveal quarterly earnings of $1.28 per share, indicating a decline of 21.5% compared to the year-ago period. Analysts forecast revenues of $12.56 billion, representing an increase of 2.7% year over year.
The current level reflects a downward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Bristol Myers metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales- Zeposia' at $165.48 million. The estimate indicates a year-over-year change of +2.8%.
The consensus among analysts is that 'Net Sales- Orencia' will reach $981.41 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Eliquis' will likely reach $4.59 billion. The estimate indicates a year-over-year change of +22.6%.
Analysts expect 'Net Sales- Yervoy' to come in at $755.79 million. The estimate suggests a change of +2.3% year over year.
Analysts forecast 'Net Sales- Abraxane- U.S.' to reach $9.24 million. The estimate indicates a year-over-year change of -61.5%.
Analysts predict that the 'Net Sales- Opdivo- U.S.' will reach $1.29 billion. The estimate indicates a year-over-year change of -11.2%.
Analysts' assessment points toward 'Net Sales- Pomalyst/Imnovid- U.S.' reaching $73.30 million. The estimate indicates a change of -87.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- International' should arrive at $44.90 million. The estimate indicates a year-over-year change of -43.2%.
The collective assessment of analysts points to an estimated 'Net Sales- Revlimid- U.S.' of $164.08 million. The estimate indicates a year-over-year change of -66.2%.
According to the collective judgment of analysts, 'Net Sales- Revlimid- International' should come in at $53.05 million. The estimate points to a change of -40.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- Reblozyl- U.S.' stands at $592.45 million. The estimate indicates a change of +19.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Reblozyl- International' will reach $146.61 million. The estimate points to a change of +21.2% from the year-ago quarter.
Over the past month, Bristol Myers shares have recorded returns of -2.2% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), BMY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Bristol Myers Squibb (BMY - Free Report) is expected to reveal quarterly earnings of $1.28 per share, indicating a decline of 21.5% compared to the year-ago period. Analysts forecast revenues of $12.56 billion, representing an increase of 2.7% year over year.
The current level reflects a downward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Bristol Myers metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales- Zeposia' at $165.48 million. The estimate indicates a year-over-year change of +2.8%.
The consensus among analysts is that 'Net Sales- Orencia' will reach $981.41 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Eliquis' will likely reach $4.59 billion. The estimate indicates a year-over-year change of +22.6%.
Analysts expect 'Net Sales- Yervoy' to come in at $755.79 million. The estimate suggests a change of +2.3% year over year.
Analysts forecast 'Net Sales- Abraxane- U.S.' to reach $9.24 million. The estimate indicates a year-over-year change of -61.5%.
Analysts predict that the 'Net Sales- Opdivo- U.S.' will reach $1.29 billion. The estimate indicates a year-over-year change of -11.2%.
Analysts' assessment points toward 'Net Sales- Pomalyst/Imnovid- U.S.' reaching $73.30 million. The estimate indicates a change of -87.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- International' should arrive at $44.90 million. The estimate indicates a year-over-year change of -43.2%.
The collective assessment of analysts points to an estimated 'Net Sales- Revlimid- U.S.' of $164.08 million. The estimate indicates a year-over-year change of -66.2%.
According to the collective judgment of analysts, 'Net Sales- Revlimid- International' should come in at $53.05 million. The estimate points to a change of -40.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- Reblozyl- U.S.' stands at $592.45 million. The estimate indicates a change of +19.9% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- Reblozyl- International' will reach $146.61 million. The estimate points to a change of +21.2% from the year-ago quarter.
View all Key Company Metrics for Bristol Myers here>>>Over the past month, Bristol Myers shares have recorded returns of -2.2% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), BMY will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .